Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering)

重组抗BCMA和CD3双特异性抗体（华兰基因工程）

Report date: 2026/03/19 17:16:13

Base Information

Drug NameRecombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering)
Drug Alias Name重组抗BCMA和CD3双特异性抗体注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-BCMAAnti-CD3
TargetsB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHualan Genetic Engineering (Henan) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHualan Genetic Engineering (Henan) Co LtdHualan Ankang Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A